Mabthera 1400mg/11.7ml Subcutanous 1 Vial (Refrigerated)

Active Ingredient: Rituximab Chronic lymphocytic leukemia: Treatment of previously untreated or previously treated CD20-positive chronic lymphocytic leukemia (CLL) (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis: Treatment of granulomatosis with polyangiitis (GPA; Wegener granulomatosis) (in combination with glucocorticoids). Microscopic polyangiitis: Treatment of microscopic polyangiitis (MPA) (in combination with glucocorticoids). Non-Hodgkin lymphomas: Treatment of CD20-positive non-Hodgkin lymphomas (NHL): Relapsed or refractory, low-grade or follicular B-cell NHL (as a single agent) Follicular B-cell NHL, previously untreated (in combination with first-line chemotherapy, and as single-agent maintenance therapy if complete or partial response to first-line rituximab with chemotherapy) Nonprogressing (including stable disease), low-grade B-cell NHL (as a single agent after first-line CVP treatment) Diffuse large B-cell NHL, previously untreated (in combination with CHOP chemotherapy [or other anthracycline-based regimen]) Rheumatoid arthritis: Treatment of moderately to severely active rheumatoid arthritis (in combination with methotrexate) in adult patients with inadequate response to one or more TNF antagonist therapies. Limitations of use: Rituximab is not recommended for use in patients with severe, active infections.